JP2021520349A5 - - Google Patents

Download PDF

Info

Publication number
JP2021520349A5
JP2021520349A5 JP2020553633A JP2020553633A JP2021520349A5 JP 2021520349 A5 JP2021520349 A5 JP 2021520349A5 JP 2020553633 A JP2020553633 A JP 2020553633A JP 2020553633 A JP2020553633 A JP 2020553633A JP 2021520349 A5 JP2021520349 A5 JP 2021520349A5
Authority
JP
Japan
Prior art keywords
ret
cancer
composition according
composition
mutation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020553633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520349A (ja
JP7422084B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/025655 external-priority patent/WO2019195471A1/en
Publication of JP2021520349A publication Critical patent/JP2021520349A/ja
Publication of JP2021520349A5 publication Critical patent/JP2021520349A5/ja
Priority to JP2021199945A priority Critical patent/JP2022022391A/ja
Priority to JP2023167564A priority patent/JP2023165937A/ja
Application granted granted Critical
Publication of JP7422084B2 publication Critical patent/JP7422084B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020553633A 2018-04-03 2019-04-03 Ret変化を有する癌の処置において使用するためのret阻害剤 Active JP7422084B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021199945A JP2022022391A (ja) 2018-04-03 2021-12-09 Ret変化を有する癌の処置において使用するためのret阻害剤
JP2023167564A JP2023165937A (ja) 2018-04-03 2023-09-28 Ret変化を有する癌の処置において使用するためのret阻害剤

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862652284P 2018-04-03 2018-04-03
US62/652,284 2018-04-03
US201862656297P 2018-04-11 2018-04-11
US62/656,297 2018-04-11
US201862657605P 2018-04-13 2018-04-13
US62/657,605 2018-04-13
US201862741683P 2018-10-05 2018-10-05
US62/741,683 2018-10-05
PCT/US2019/025655 WO2019195471A1 (en) 2018-04-03 2019-04-03 Ret inhibitor for use in treating cancer having a ret alteration

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021199945A Division JP2022022391A (ja) 2018-04-03 2021-12-09 Ret変化を有する癌の処置において使用するためのret阻害剤
JP2023167564A Division JP2023165937A (ja) 2018-04-03 2023-09-28 Ret変化を有する癌の処置において使用するためのret阻害剤

Publications (3)

Publication Number Publication Date
JP2021520349A JP2021520349A (ja) 2021-08-19
JP2021520349A5 true JP2021520349A5 (cg-RX-API-DMAC7.html) 2021-09-30
JP7422084B2 JP7422084B2 (ja) 2024-01-25

Family

ID=66223846

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020553633A Active JP7422084B2 (ja) 2018-04-03 2019-04-03 Ret変化を有する癌の処置において使用するためのret阻害剤
JP2021199945A Pending JP2022022391A (ja) 2018-04-03 2021-12-09 Ret変化を有する癌の処置において使用するためのret阻害剤
JP2023167564A Withdrawn JP2023165937A (ja) 2018-04-03 2023-09-28 Ret変化を有する癌の処置において使用するためのret阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021199945A Pending JP2022022391A (ja) 2018-04-03 2021-12-09 Ret変化を有する癌の処置において使用するためのret阻害剤
JP2023167564A Withdrawn JP2023165937A (ja) 2018-04-03 2023-09-28 Ret変化を有する癌の処置において使用するためのret阻害剤

Country Status (26)

Country Link
US (5) US20210100795A1 (cg-RX-API-DMAC7.html)
EP (2) EP4353317A3 (cg-RX-API-DMAC7.html)
JP (3) JP7422084B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200139749A (cg-RX-API-DMAC7.html)
AU (1) AU2019247766A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020020273A2 (cg-RX-API-DMAC7.html)
CA (1) CA3096043A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002544A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200522A (cg-RX-API-DMAC7.html)
DK (1) DK3773589T3 (cg-RX-API-DMAC7.html)
ES (1) ES2970041T3 (cg-RX-API-DMAC7.html)
FI (1) FI3773589T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240124T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065374T2 (cg-RX-API-DMAC7.html)
IL (1) IL277629A (cg-RX-API-DMAC7.html)
LT (1) LT3773589T (cg-RX-API-DMAC7.html)
MX (1) MX2020010417A (cg-RX-API-DMAC7.html)
MY (1) MY203645A (cg-RX-API-DMAC7.html)
PE (1) PE20210096A1 (cg-RX-API-DMAC7.html)
PL (1) PL3773589T3 (cg-RX-API-DMAC7.html)
PT (1) PT3773589T (cg-RX-API-DMAC7.html)
RS (1) RS65127B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202009681YA (cg-RX-API-DMAC7.html)
SI (1) SI3773589T1 (cg-RX-API-DMAC7.html)
WO (1) WO2019195471A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006072B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
US11666570B2 (en) * 2019-07-11 2023-06-06 The Board Of Trustees Of The Leland Stanford Junior University Diagnosis and regulation of epidermal differentiation and cancer cell activity
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
US11946935B2 (en) * 2020-08-25 2024-04-02 Regents Of The University Of Minnesota Circulating tumor markers for meningiomas
JP1746261S (ja) * 2022-10-17 2023-06-14 量子暗号鍵伝送機

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030024659A (ko) 2000-02-17 2003-03-26 암겐 인코포레이티드 키나제 억제제
WO2004009087A1 (en) 2002-07-24 2004-01-29 University Of Cincinnati 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases
JP5138938B2 (ja) 2003-12-19 2013-02-06 プレキシコン インコーポレーテッド Ret調節剤の開発のための化合物および方法
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
AU2006244203B2 (en) 2005-05-09 2012-05-03 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
WO2006128042A2 (en) 2005-05-26 2006-11-30 The Johns Hopkins University Methods of identifying mutations in nucleic acid
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
WO2007087245A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Ret tyrosine kinase inhibition
CN104706637A (zh) 2006-05-18 2015-06-17 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
US20090048214A1 (en) 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
WO2009003136A1 (en) 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
JP2010533158A (ja) 2007-07-09 2010-10-21 アストラゼネカ アクチボラグ 化合物類−945
BRPI0814441A2 (pt) 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
WO2009018415A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
WO2009100536A1 (en) 2008-02-15 2009-08-20 Methylgene Inc. Inhibitors of kinase activity with 1,2-di-cyclyl substituted alkyne structures
EP2313091A4 (en) 2008-07-14 2012-04-04 Univ Kingston PHARMACEUTICAL COMPOSITIONS WITH RET-HEMMERN AND METHOD FOR THE TREATMENT OF CANCER
AU2010229140A1 (en) 2009-03-24 2011-11-10 Msd K.K. Novel aminopyridine derivatives having Aurora A selective inhibitory action
EP2440052A4 (en) 2009-06-08 2013-01-23 Abraxis Bioscience Llc TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
EP2440053A4 (en) 2009-06-09 2012-10-31 California Capital Equity Llc BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
PH12012500809A1 (en) 2009-10-30 2012-11-26 Ariad Pharma Inc Methods and compositions for treating cancer
CA2780892C (en) 2009-11-13 2017-02-14 Genosco Kinase inhibitors
WO2013018882A1 (ja) 2011-08-04 2013-02-07 独立行政法人国立がん研究センター Kif5b遺伝子とret遺伝子との融合遺伝子、並びに該融合遺伝子を標的としたがん治療の有効性を判定する方法
WO2013028817A1 (en) 2011-08-23 2013-02-28 Foundation Medicine , Inc. Novel kif5b-ret fusion molecules and uses thereof
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20130096136A1 (en) 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
US10023855B2 (en) 2011-10-31 2018-07-17 Macrogen, Inc. Fusion protein comprising C-terminal domain of RET protein and use thereof as a diagnosing marker
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CN104169260A (zh) 2012-03-09 2014-11-26 卡尔那生物科学株式会社 新三嗪衍生物
JP2015109806A (ja) 2012-03-22 2015-06-18 アステラス製薬株式会社 新規ret融合体の検出法
ES2645984T3 (es) 2012-04-25 2017-12-11 Raqualia Pharma Inc Derivados de pirrolopiridinona como bloqueadores de TTX-S
US20150099721A1 (en) 2012-05-10 2015-04-09 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
JPWO2014017491A1 (ja) 2012-07-26 2016-07-11 国立研究開発法人国立がん研究センター Cep55遺伝子とret遺伝子との融合遺伝子
JP6513567B2 (ja) 2012-09-07 2019-05-15 エクセリクシス, インク. 肺腺癌の治療で使用するためのmet、vegfr、およびretの阻害剤
PL2902029T3 (pl) 2012-09-25 2019-01-31 Chugai Seiyaku Kabushiki Kaisha Inhibitor RET
EP2917214B1 (en) 2012-11-07 2019-08-28 Nerviano Medical Sciences S.r.l. Substituted pyrimidinyl and pyridinyl-pyrrolopyridinones, process for their preparation and their use as kinase inhibitors
TWI629266B (zh) 2012-12-28 2018-07-11 藍印藥品公司 纖維母細胞生長因子受體之抑制劑
BR112015019590A2 (pt) 2013-02-25 2017-07-18 Bristol Myers Squibb Co derivados de ácido betulínico modificado com c-3 alquila e alquenila úteis no tratamento de hiv
MX2015012286A (es) 2013-03-15 2016-05-31 Glaxosmithkline Ip Dev Ltd Derivados de piridina como inhibidores de cinasa reordenada durante transfección.
WO2014160521A1 (en) 2013-03-15 2014-10-02 Blueprint Medicines Corporation Piperazine derivatives and their use as kit modulators
WO2014147640A2 (en) 2013-03-19 2014-09-25 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for the preparation of anagliptin
WO2015006875A1 (en) 2013-07-18 2015-01-22 Methylgene Inc. Process for the preparation of substituted pyrimidines
EP3037547A1 (en) 2013-08-20 2016-06-29 National Cancer Center New fusion gene detected in lung cancer
US9334263B2 (en) 2013-10-17 2016-05-10 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015108992A1 (en) 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
US9688680B2 (en) 2014-08-04 2017-06-27 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
EP3517526B1 (en) 2014-09-10 2020-08-19 GlaxoSmithKline Intellectual Property Development Limited Pyridinones as rearranged during transfection (ret) inhibitors
BR112017004897A2 (pt) 2014-09-10 2017-12-12 Glaxosmithkline Ip Dev Ltd compostos inovadores como inibidores rearranjados durante a transfecção (ret)
EP3218378B1 (en) 2014-11-14 2020-01-08 Nerviano Medical Sciences S.r.l. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
US10202365B2 (en) 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
CN104844567B (zh) 2015-04-23 2017-03-29 暨南大学 一种中间体1‑(3‑氯‑2‑吡啶基)‑3‑溴‑1h‑5‑吡唑甲酸的合成方法
CA2992586A1 (en) 2015-07-16 2017-01-19 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
BR112018001190A2 (pt) 2015-07-24 2018-09-11 Blueprint Medicines Corp composições úteis para tratar distúrbios relacionados a kit e pdfgr
WO2017035354A1 (en) 2015-08-26 2017-03-02 Blueprint Medicines Corporation Compounds and compositions useful for treating disorders related to ntrk
CN105255927B (zh) 2015-09-30 2018-07-27 温州医科大学附属第一医院 一种kiaa1217-ret融合基因
RS65069B1 (sr) 2015-11-02 2024-02-29 Blueprint Medicines Corp Inhibitori ret-a
BR112018008908A2 (pt) 2015-11-02 2018-11-27 Janssen Pharmaceutica Nv anticorpos anti-il1rap, moléculas de ligação ao antígeno biespecíficas que se ligam il1rap e cd3, e seus usos
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
SG10201912607SA (en) 2015-11-19 2020-02-27 Blueprint Medicines Corp Compounds and compositions useful for treating disorders related to ntrk
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
AR107912A1 (es) 2016-03-17 2018-06-28 Blueprint Medicines Corp Inhibidores de ret
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
HRP20221051T8 (hr) 2016-04-15 2023-07-21 Cancer Research Technology Limited Heterociklički spojevi kao inhibitori ret kinaze
KR102706837B1 (ko) 2016-04-15 2024-09-19 캔써 리서치 테크놀로지 리미티드 Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
FI3442977T3 (fi) 2016-04-15 2023-09-26 Blueprint Medicines Corp Aktiviinireseptorin kaltaisen kinaasin estäjät
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
US10035789B2 (en) 2016-07-27 2018-07-31 Blueprint Medicines Corporation Compounds useful for treating disorders related to RET
CN110022900A (zh) 2016-09-08 2019-07-16 蓝图药品公司 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
CN106749231B (zh) 2016-10-09 2019-03-01 南京纳丁菲医药科技有限公司 萘啶化合物和药物组合物及它们的应用
TWI752098B (zh) 2016-10-10 2022-01-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド RETキナーゼ阻害剤としての置換ピラゾロ[1,5−a]ピラジン化合物
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
WO2018183712A1 (en) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US20210290620A1 (en) * 2017-05-15 2021-09-23 Blueprint Medicines Corporation Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
EP3641776B1 (en) 2017-06-23 2023-10-18 San Diego State University Research Foundation Atropisomerism for enhanced kinase inhibitor selectivity
CN109180677A (zh) 2017-06-30 2019-01-11 厦门大学 取代芳基醚类化合物、其制备方法、药用组合物及其应用
ES3074838T3 (es) 2017-07-07 2026-07-23 Medicover Public Co Ltd Análisis paralelo multiplexado con enriquecimiento de blancos para la evaluación de biomarcadores tumorales
CN107980784B (zh) 2017-12-13 2020-05-26 中国农业大学 5-氨基吡唑类化合物在调节植物生长方面的应用
RS63787B1 (sr) 2017-12-19 2022-12-30 Turning Point Therapeutics Inc Makrociklična jedinjenja za lečenje bolesti
EP3740486A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CN111630054B (zh) 2018-01-18 2023-05-09 奥瑞生物药品公司 作为RET激酶抑制剂的取代的吡唑并[3,4-d]嘧啶化合物
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN108341782A (zh) 2018-03-30 2018-07-31 南京哈柏医药科技有限公司 3-氨基-5-甲基吡唑的合成工艺
SG11202009681YA (en) 2018-04-03 2020-10-29 Blueprint Medicines Corp Ret inhibitor for use in treating cancer having a ret alteration
EP3833372A4 (en) 2018-08-10 2022-06-08 Blueprint Medicines Corporation TREATMENT OF EGFR MUTANT CANCER
CN111440151A (zh) 2020-03-25 2020-07-24 魏威 制备抗肿瘤药普拉赛替尼的方法
CN111362923A (zh) 2020-03-25 2020-07-03 魏威 制备ret抑制剂普拉塞替尼的方法、以及普拉塞替尼的中间体及其制备方法
WO2021243192A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CR20220666A (es) 2020-05-29 2023-05-05 Blueprint Medicines Corp Composiciones farmacéuticas de pralsetinib
US20240059672A1 (en) 2020-12-04 2024-02-22 Blueprint Medicines Corporation Method of preparing pralsetinib

Similar Documents

Publication Publication Date Title
JP2020519672A5 (cg-RX-API-DMAC7.html)
Gonzalez-Angulo et al. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer
Hof et al. Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma
CN103533961B (zh) 以表皮生长因子受体为靶向的治疗癌症的组合方法
Simo et al. Nasopharyngeal carcinoma: United Kingdom national multidisciplinary guidelines
de la Rochefordiere et al. PIK3CA pathway mutations predictive of poor response following standard radiochemotherapy±cetuximab in cervical cancer patients
Pirker et al. Adjuvant therapy in patients with completely resected non–small-cell lung cancer: current status and perspectives
Rivera et al. Cetuximab, its clinical use and future perspectives
Luedke et al. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation
Qin et al. Basket trials for intractable cancer
JP2020527139A5 (cg-RX-API-DMAC7.html)
JP7422084B2 (ja) Ret変化を有する癌の処置において使用するためのret阻害剤
RU2019114079A (ru) Лечение er+ рака молочной железы лазофоксифеном
JP2024506612A5 (cg-RX-API-DMAC7.html)
JP2022502399A5 (cg-RX-API-DMAC7.html)
RU2019114031A (ru) Способы и композиции для tusc2-иммунотерапии
Goldwirt et al. Reply to ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance’by Funck-Brentano et al.
Stoffel Targeted therapies for solid tumors: current status and future perspectives
JP2023515687A5 (cg-RX-API-DMAC7.html)
Baek et al. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
WO2018004465A1 (en) Maintenance therapy for the treatment of cancer
Liubota et al. The impact of locoregional treatment on survival of patients with primary metastatic breast cancer
Alzarkali et al. Ipilimumab and Nivolumab After Disease Progression on Single Agent Immunotherapy in Mismatch Repair Deficient Metastatic Colorectal Cancer
Hammer et al. Celiac plexus radiosurgery, a new modality for cancer pain management–final results of a phase II clinical trial
RU2021131604A (ru) Соединения с противоопухолевой активностью против раковых клеток, несущих инсерции в экзоне 21 her2